OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS Stock

Certificat

DE000HG2L5L7

Market Closed - BOERSE MUENCHEN 09:45:00 2024-05-31 EDT
12.26 EUR -1.53% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - ROCHE GS
1 month-8.10%
3 months-9.92%
Date Price Change
24-05-31 12.26 -1.53%
24-05-30 12.45 +2.47%
24-05-29 12.15 +0.25%
24-05-28 12.12 +0.41%
24-05-27 12.07 +0.50%

Real-time BOERSE MUENCHEN

Last update May 31, 2024 at 09:45 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying ROCHE HOLDING AG
Issuer HSBC
WKN HG2L5L
ISINDE000HG2L5L7
Date issued 2022-04-22
Strike 349.8 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 1.98
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.69
Lowest since issue 1.95

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus